Literature DB >> 19383335

Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors.

John C McAuliffe, Wei-Lein Wang, Giovanni M Pavan, Sabrina Pricl, Dan Yang, Su S Chen, Alexander J F Lazar, Raphael E Pollock, Jonathan C Trent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19383335      PMCID： PMC5527764          DOI： 10.1016/j.molonc.2008.05.002

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


× No keyword cloud information.
  7 in total

1.  Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors.

Authors:  John C McAuliffe; Wei-Lein Wang; Giovanni M Pavan; Sabrina Pricl; Dan Yang; Su S Chen; Alexander J F Lazar; Raphael E Pollock; Jonathan C Trent
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 6.603

2.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

3.  Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.

Authors:  Jayesh Desai; Sridhar Shankar; Michael C Heinrich; Jonathan A Fletcher; Christopher D Fletcher; Judi Manola; Jeffrey A Morgan; Christopher L Corless; Suzanne George; Kemal Tuncali; Stuart G Silverman; Annick D Van den Abbeele; Eric van Sonnenberg; George D Demetri
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

4.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.

Authors:  Samuel Singer; Brian P Rubin; Marcia L Lux; Chang-Jie Chen; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

5.  A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Authors:  Lei L Chen; Jonathan C Trent; Elsie F Wu; Gregory N Fuller; Latha Ramdas; Wei Zhang; Austin K Raymond; Victor G Prieto; Caroline O Oyedeji; Kelly K Hunt; Raphael E Pollock; Barry W Feig; Kimberly J Hayes; Haesun Choi; Homer A Macapinlac; Walter Hittelman; Marco A Velasco; Shreyaskumar Patel; Michael A Burgess; Robert S Benjamin; Marsha L Frazier
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

6.  Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.

Authors:  Jerzy Lasota; Christopher L Corless; Michael C Heinrich; Maria Debiec-Rychter; Raf Sciot; Eva Wardelmann; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus; Sonja E Steigen; Jerzy Stachura; Agnieszka Wozniak; Cristina Antonescu; Ondrej Daum; Javier Martin; Javier Garcia Del Muro; Markku Miettinen
Journal:  Mod Pathol       Date:  2008-02-01       Impact factor: 7.842

7.  Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients.

Authors:  E Tamborini; S Pricl; T Negri; M S Lagonigro; F Miselli; A Greco; A Gronchi; P G Casali; M Ferrone; M Fermeglia; A Carbone; M A Pierotti; S Pilotti
Journal:  Oncogene       Date:  2006-06-05       Impact factor: 9.867
  7 in total
  7 in total

1.  NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Cristina R Antonescu; Ronald P DeMatteo; Kristen N Ganjoo; Robert G Maki; Peter W T Pisters; Chandrajit P Raut; Richard F Riedel; Scott Schuetze; Hema M Sundar; Jonathan C Trent; Jeffrey D Wayne
Journal:  J Natl Compr Canc Netw       Date:  2010-04       Impact factor: 11.908

2.  Toward personalized, targeted therapy of gastrointestinal stromal tumor.

Authors:  Jonathan C Trent
Journal:  Gastrointest Cancer Res       Date:  2008-09

3.  Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors.

Authors:  John C McAuliffe; Wei-Lein Wang; Giovanni M Pavan; Sabrina Pricl; Dan Yang; Su S Chen; Alexander J F Lazar; Raphael E Pollock; Jonathan C Trent
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 6.603

4.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.

Authors:  Carlos A Torres-Cabala; Wei-Lien Wang; Jonathan Trent; Dan Yang; Su Chen; John Galbincea; Kevin B Kim; Scott Woodman; Michael Davies; Jose A Plaza; J W Nash; Victor G Prieto; Alexander J Lazar; Doina Ivan
Journal:  Mod Pathol       Date:  2009-08-28       Impact factor: 7.842

5.  Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.

Authors:  Elena Conca; Claudia Miranda; Valentina Dal Col; Elena Fumagalli; Giuseppe Pelosi; Mara Mazzoni; Maurizio Fermeglia; Erik Laurini; Marco A Pierotti; Silvana Pilotti; Angela Greco; Sabrina Pricl; Elena Tamborini
Journal:  Mol Oncol       Date:  2013-03-21       Impact factor: 6.603

6.  Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.

Authors:  Damien Kee; John R Zalcberg
Journal:  Ther Adv Med Oncol       Date:  2012-09       Impact factor: 8.168

7.  Molecular and functional characterization of a new 3' end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib.

Authors:  Vittorio Perfetti; Erik Laurini; Suzana Aulić; Maurizio Fermeglia; Roberta Riboni; Marco Lucioni; Elena Dallera; Sara Delfanti; Luigi Pugliese; Francesco Saverio Latteri; Andrea Pietrabissa; Sabrina Pricl
Journal:  Oncotarget       Date:  2017-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.